Background
==========

The brain's energy needs are mainly met by neurovascular regulation of cerebral blood flow (CBF) ([@B66]; [@B22]), realized by the neurovascular unit (NVU). The NVU consists of arterial/arteriolar vascular smooth-muscle cells (VMSCs), endothelial cells, neuroglia (notably astrocytes), and pericytes. Pericytes play a crucial role in the formation and functionality of the selectively permeable space that is the blood--brain barrier (BBB), and BBB disruption is a classic marker of vascular dysfunction. Neurovascular dysfunction leads to failure to meet neuronal energy needs, which leads to oxidative stress and eventual neuronal death.

Vascular Role In Alzheimer's Disease
====================================

While the 𝜀4 allele of the apolipoprotein E (APOE) gene is an acknowledged genetic risk factor found in 40--80% of Alzheimer's disease (AD) patients ([@B75]), and amyloid plaques are a hallmark of AD, an approximated 60--90% of AD patients also exhibit cerebrovascular pathologies ([@B4]), supporting the vascular theory of AD. In brief, the current understanding is that genetic, environmental, and lifestyle factors may all predispose individuals to damage to the NVU (**Figure [1](#F1){ref-type="fig"}**). Soluble amyloid beta (Aβ), which predates Aβ plaques, deregulates cerebrovascular function by activating a free-radical cascade ([@B57]), leading to compromised microvascular integrity ([@B20]), and reduced CBF. Aβ is known to interact with endothelin-1 ([@B47]) and myocardin ([@B63]) to promote vascular hypercontractility. Moreover, the cholinergic deficit in AD can result in a reduction of cholinergic input to cortical blood vessels ([@B17]). Furthermore, Aβ-mediated pericyte degeneration leads to BBB breakdown, increasing the perivascular accumulation of neurotoxins. The various pathways of vascular dysfunction can lead to increasing vascular tortuosity and decreasing vascular reactivity ([@B5]), compromising Aβ clearance and eventually lead to neuronal death. Paradoxically, tau pathology has been associated with an increase in regional vascular reactivity ([@B81]), a controversy that is still under investigation.

![Vascular involvement in AD, as depicted in a "2-hit model" of neurovascular dysfunction. Genetic risk (including due to APOE 𝜀4) predispose individuals to amyloid deposition. Modified from [@B48] with permission.](fnagi-10-00170-g001){#F1}

Irrespective of the specific disease mechanism, vascular deficits have been demonstrated as a promising early indicator of AD. Non-invasive functional magnetic-resonance imaging (MRI) has provided strong evidence that CBF can be used to distinguish between at-risk individuals, patients and normal controls ([@B44]). In addition, perfusion deficits have been associated with decreased functional connectivity despite maintained glucose metabolism ([@B31]). Interventions to re-establish perfusion have been advocated as a promising preventative treatment ([@B19]). However, perfusion is a mixture of neuronal and vascular contributions, and unraveling the vascular mechanisms of AD etiology requires a more vascularly specific and routinely adoptable vascular marker. In this respect, there is early evidence that deficits in cerebrovascular reactivity (CVR) are detectable before those in CBF ([@B85]). Indeed, this was demonstrated through quantitative cerebrovascular resistance, defined as the ratio of mean-arterial blood pressure to CBF ([@B83]). Compared to CBF, resistance was found to be more sensitive at distinguishing amyloid-positive from amyloid-negative older populations as well as being more predictive of dementia conversion.

CVR and Measurement Techniques
==============================

A recent review by [@B28] provides an excellent overview of CVR measurement in AD using carbon-dioxide (CO~2~) challenges with various imaging modalities. CVR is a vasodilatory or constrictive reaction of a blood vessel to a stimulus. CVR is a well-established indicator of vascular reserve and autoregulatory efficiency. CVR decline has been associated with normal aging ([@B53]), and is the most reliable neuroimaging predictor of impending cerebrovascular disease ([@B59]).

Vascular Stimulus and CVR
-------------------------

Qualitative CVR information can be gleaned from the functional MRI (fMRI) response to any task ([@B23]), but when quantitative CVR values are desired, vascular agents are generally required. Strong CBF responses can be induced by intravascular CO~2~ alterations, with CO~2~ inspiration thought as the optimal form of stimulus ([@B24]). While breathing and blood flow can both be regulated through the midbrain CO~2~ chemoreceptors, CO~2~-related blood pH changes are also actively regulated as part of maintaining homeostasis. Thus, hypercapnic challenges, in which the arterial CO~2~ content is increased, activate VMSC potassium channels ([@B1]), leading to large CBF increases without a significant concomitant increase in metabolic rate ([@B14]; [@B42]). In addition, nitric oxide, which is synthesized locally following glutamate receptor activity, has also been implicated in the modulation of vasodilatory effects produced by CO~2~ ([@B37]).

End-tidal CO~2~ pressure (PETCO~2~) is an easily measured surrogate for arterial CO~2~ (PaCO~2~) ([@B3]). PETCO~2~ is measured as the peak expired CO~2~, typically 35--40 mmHg in healthy individuals, and directly reflects alveolar CO~2~. CBF increases by 3--4% per mmHg increase in PETCO~2~, reaching its highest level when PETCO~2~ is elevated by 10--20 mmHg above normal resting value ([@B11]). PETCO~2~ reductions result in CBF decline by approximately 3% per 1 mmHg change ([@B39]).

CO~2~-Based CVR Mapping Using MRI: Methods
------------------------------------------

The clinical utility of CO~2~-based CVR quantification was established using transcranial Doppler ultrasound (TCD) ([@B1]), positron-emission tomography ([@B40]) and dynamic X-ray computed tomography ([@B13]). While fMRI is not the most established method of assessing CVR, it offers marked advantages including richer spatial information and minimal invasiveness ([@B38]). CVR has been reliably assessed using CO~2~ fMRI in both gray and white matter ([@B78]). In the absence of a CO~2~ delivery apparatus, breathing challenges such as breath-holding ([@B10]; [@B60]) and cued deep breathing ([@B9]) have been proposed as alternative ways to modulate intravascular CO~2~ (see **Table [1](#T1){ref-type="table"}**). A comparison of breath-holding and inhaled-CO~2~ approaches reveals important CVR dependence on methodology ([@B77]), but the reproducibility of both approaches has been established in healthy young controls ([@B46]; [@B10]).

###### 

Strengths and weaknesses of various CO~2~-based CVR protocols.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Approach                 Strengths                                                                 Weaknesses
  ------------------------ ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  End-tidal forcing        • Accurate targeting of PETCO~2~\                                         • Requires complex instrumentation\
                           • Can be used to produce complex PETCO~2~ shapes\                         • Feedback mechanism reduces response speed\
                           • Produces quantitative CVR                                               • The hypercapnic challenge may induce discomfort

  Prospective targeting    • Accurate targeting of PETCO~2~\                                         • Requires complex instrumentation\
                           • Feed-forward mechanism enhances response speed\                         • Requires estimation of [VO2max]{.ul}\
                           • Can be used to produce complex PETCO~2~ shapes\                         • The hypercapnic challenge may induce discomfort
                           • Produces quantitative CVR                                               

  Manually blended gases   • Requires simple instrumentation and set up\                             • PETCO~2~ response rate depends on ventilation level and cannot be controlled\
                           • Produces quantitative CVR                                               • PETCO~2~ not actively targeted, so resulting challenge may vary by individual

  Breath-holding           • Requires no additional instrumentation                                  • Actual PETCO2 cannot be measured, so CVR not quantitative\
                                                                                                     • Relationship between breath-hold and PETCO~2~ depends on numerous factors\
                                                                                                     • Requires active subject cooperation, may vary

  Cued deep breathing      • Requires no additional instrumentation                                  • Actual PETCO2 cannot be measured, so CVR not quantitative\
                                                                                                     • Relationship between deep breathing and PETCO~2~ depends on numerous factors\
                                                                                                     • Requires active subject cooperation, may vary

  Resting state            • Requires little to no additional instrumentation\                       • MRI response to CO~2~ is more sensitive to contamination by motion and other artifacts, given the low PETCO~2~ fluctuation amplitude
                           • Requires minimal subject cooperation\                                   
                           • Does not induce discomfort\                                             
                           • CVR estimated from multiple PETCO~2~ values instead of block averages   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CO~2~-based CVR measured using fMRI has been widely applied and extensively cross-validated ([@B35]). Robust hypercapnia can be induced through manually adjusted administration of blended gases ([@B18]), end-tidal forcing ([@B62]) or more recently, computerized PETCO~2~ targeting ([@B71]; [@B54]). The latter method entails the most lengthy set up but also provides immediate and robust PETCO~2~ suppression (hypocapnia) ([@B6]), and has been proposed as part of a rapid CVR-mapping protocol for routine use ([@B6], [@B7]).

In the clinical realm, the main considerations in choosing a CVR-mapping methodology are: (1) How to assess CVR in the most non-invasive manner? (2) How to interpret the CVR information?

Consideration for Non-invasiveness
----------------------------------

As one of the earliest ways to induce PETCO~2~ elevation ([@B64]), breath-holding typically does not allow the calculation of quantitative CVR, as all participants are assumed to perform breath-holds in similar manners and the actual PETCO~2~ cannot be monitored during the challenge. The lack of PETCO~2~ monitoring is particularly concerning, as the actual change in PETCO~2~ achieved by a breath-hold depends on multiple factors, including the resting metabolic rate of the subject, lung size, recent ventilation history and whether the breath-hold is post-inspiration or post-expiration. Moreover, as typical breath-holds last 15--20 s, there are reports of poor subject compliance ([@B41]), particularly when elderly participants are involved. Despite these drawbacks, breath-holding-based CVR mapping has a key advantage of requiring the least instrumentation, thus allowing it to be implemented in almost any MRI scan session. Ongoing research aims to improve the robustness of breath-hold CVR mapping ([@B10]), although clinical validation remains far from extensive.

Even less invasive than breath-holding, resting-state fMRI has offered a unique window to glean CVR information. Notably, [@B45] reported a comparison of the resting-state fMRI fluctuation amplitude (voxel-wise temporal standard-deviation) as a CVR surrogate. This type of "unconstrained" or "task-free" CVR protocol does not require cooperation from participants, and is thus a promising direction of research that will likely attract tremendous attention from clinical studies. This topic will be further discussed as part of a proposed future trend.

Consideration for Data Interpretation
-------------------------------------

Currently, the de-facto standard protocol to quantitative CVR mapping with MRI remains CO~2~ inhalation, notably controlled using computerized targeting ([@B46]; [@B24]; [@B72], [@B73]; [@B61]; [@B68]; [@B25]). Despite the complex set up, this approach has been extensively used and validated clinically. The use of modern breathing circuits also allows the CO~2~ challenge to follow nearly any shape. However, there has yet to be a consensus as to the level, duration and pattern of PETCO~2~ perturbation. As different stimulus designs likely have different vaso-stimulating capacities and hence may reveal different CVR patterns, the choice of challenge will be critical, not only in comparing across studies but also across the same individuals over time ([@B24]).

Based on prospective targeting of stepwise PETCO~2~ changes, researchers at Toronto Western Hospital (TWH) pioneered the use of an uneven task design -- one short block followed by longer block ([@B74]), both typically elevating PETCO~2~ by 10 mmHg. This design is motivated by the desire to derive more accurate estimates of CVR response time, and ([@B21]; [@B61]), which may reflect regional arterial-transit time. Additionally, the same group proposed the use of progressive hypercapnia (CO~2~ ramps) ([@B25]), in which both hypercapnia and hypocapnia are progressively induced through a ramp stimulus. It has been demonstrated that different segments of the ramp, which resulted in PETCO~2~ values of 30--50 mmHg, reveal different spatial patterns in CVR that could complement the conventional CVR information ([@B25]). Alternatively, the use of a sinusoidal pattern allows direct estimation of response delay (as the phase in the corresponding sinusoidal CVR response), and has allowed the development of a CVR protocol as short as 5 min ([@B7]). Such a design makes use of both hypercapnia and hypocapnia for CVR estimation, rendering estimates more robust against biases due to basal vascular tone ([@B33]). Further reducing scan time is a 1-min blended-gas protocol with 5% CO~2~ ([@B84]; [@B7]), which has compared favorably against longer designs. These stimulation designs are summarized in **Figure [2](#F2){ref-type="fig"}**, and research is ongoing to validate the unique utility of each design, and it is likely that CVR measurements produced by these various methods are not directly comparable.

![A summary of designs for various PETCO~2~ challenges in the literature.](fnagi-10-00170-g002){#F2}

Concurrently, the emergence of arterial-spin labeling (ASL) MRI for CBF-based CVR mapping has added a new dimension to the choice of methods. In particular, CBF-based maps, while lower in signal-to-noise ratios (SNRs), can in fact provide more vascular-driven and thus less biased CVR quantification than BOLD fMRI ([@B33]), as demonstrated by comparisons with TCD ([@B26]). Great strides have been made in extending the use of ASL-based CVR mapping into aging research ([@B51]), and ASL is now ubiquitously used in the study of AD ([@B2]).

AD-Associated Findings in Human CVR Mapping Using MRI
=====================================================

Cerebrovascular reactivity compromises in the middle-cerebral artery in AD, mainly measured using blended-CO~2~ method, is a well-established TCD-based finding ([@B50]; [@B67]; [@B80]; [@B32]). While the use of MRI-based CVR mapping in AD is still limited, its adoption is on the cusp of expansion due to rapid methodological developments.

Using MRI, such CVR reductions have been localized to the prefrontal, anterior cingulate and insular regions ([@B85]). Interestingly, while this pattern overlapped little with that of CBF deficits (found in the temporal and parietal regions), it agreed with the localization of amyloid deposition ([@B85]), suggesting that CVR has unique sensitivity to AD pathology (**Figure [3A](#F3){ref-type="fig"}**). Moreover, cortical and white-matter CVR deficits have been linked to the incidence of leukoaraiosis ([@B85]; [@B68]). Such reductions in CVR echo postmortem observations of vascular dysfunction ([@B15]), and can be the result of a number of structural changes in the vasculature, including cerebral amyloid angiopathy (CAA), astrocytic end-feet swelling, pericyte degeneration, basement-membrane hypertrophy and endothelial-cell metabolic abnormalities ([@B34]; [@B55]).

![MRI-based CVR maps in AD and APOE gene carriers. **(A)** Frontal, cingular, and insular CVR deficits are found in AD patients. Figure is modified from [@B85] with permission. **(B)** Young 𝜀4 carriers manifest widespread CVR deficits compared to 𝜀3 homozygotes. Figure is modified from [@B76] with permission.](fnagi-10-00170-g003){#F3}

Cerebrovascular reactivity deficits have been discovered amongst young APOE 𝜀4 gene carriers ([@B32]), even when compared to 𝜀3 homozygotes ([@B76]) (**Figure [3B](#F3){ref-type="fig"}**). Such deficits are found to be widespread, notably in the prefrontal and parahippocampal regions, bolstering the hypothesis that genetic predisposition to vascular disease contributes to the vulnerability of 𝜀4-carriers to late-life pathology ([@B48]).

It is increasingly recognized that vascular deficits may be the most accessible physiological treatment target in the effort to delay dementia onset, and approaches that enhance perfusion have demonstrated potential therapeutic value ([@B19]). Predicting progression of preclinical AD amongst mild-cognitive impaired (MCI) individuals has been a key research focus. Using breath-hold TCD, the predictive value of CVR ([@B69]) in terms of MCI-to-AD conversions has been demonstrated ([@B12]).

In light of the overwhelming influence of vascular risk factors in AD progression, the lines between vascular deficits in AD and other types of dementia can become blurred in later stages of the disease, as will be discussed in later sections. As a case in point, given the rampant occurrence of CAA amongst suspected AD patients, the vascular dysfunction can produce deleterious oxidative stress that can promote ischemia and accelerate AD progression ([@B27]; [@B8]). Furthermore, CVR may be a more sensitive early marker of AD severity ([@B85]). It is conceivable that a diseased vasculature may sustain normal perfusion but reveal an abnormal response to a stress test such as used in CVR mapping ([@B24]). Nonetheless, as an increasing amount of CVR data is generated using BOLD fMRI, it is also important to note that microvascular CVR is more reflective of AD severity ([@B43]), while the BOLD fMRI signal is generally dominated by large-vessels. This is true at clinical field strengths (1.5 or 3 Tesla) and using either gradient- or spin-echo BOLD. ASL, on the other hand, is likely more sensitive to capillaries and arterioles, and should be the most natural alternative for CVR mapping.

There are numerous fMRI studies that report age-related differences in the BOLD response amplitude or extent, but as the BOLD response to neuronal stimuli is intrinsically modulated by CVR, one must be cautioned against interpreting age-related BOLD differences as neuronal differences. This is also true of resting-state fMRI, where functional connectivity has been found to vary with CVR ([@B29]; [@B49]; [@B16]).

Research Gaps and Emerging Topics
=================================

As stated earlier, the most commonly reported challenge in acquiring CVR maps in clinical research pertains to the need for subject cooperation. This is true for all of the stimulus designs described thus far, imposing a fundamental limitation on the routine use of CVR mapping amongst patients. Very recently, resting-state methods that do not require CO~2~ perturbation have flourished ([@B30]; [@B41]; [@B52]). Resting-state CVR methods rely on intrinsic fluctuations in the BOLD fMRI signal, and may significantly broaden the accessibility of CVR mapping to clinical researchers. Additionally, beyond the magnitude of CVR, the dynamic features of the fMRI response can also provide useful information. A slowing of the CVR response has been shown to characterize vascular lesions ([@B61]), adding a dimension to the utility of CVR mapping.

The response of the cerebral circulation to a changing arterial CO~2~ concentration is not linear -- the circulatory response follows a sigmoidal shape, and is greater for hypercapnia than to hypocapnia ([@B56]; [@B58]; [@B65]). Moreover, it is critical to note that while CVR is traditionally defined as a blood-flow response (as is the case in TCD, PET, and CT), the BOLD signal is not a direct measure of CBF. Rather, BOLD is modulated by CBF, CBV, and baseline oxidative metabolism, not to mention a series of field-dependent physical variables. Thus, the assumption of a linear relationship between the BOLD and CBF responses to CO~2~ is likely tenuous. Specifically, it is widely known that the BOLD response varies with CBF in a non-linear fashion ([@B36]). This non-linearity is superimposed in the inherently sigmoidal vascular response to CO~2~ ([@B3]). Such non-linear CVR changes have been demonstrated through a comparison with CBF-based CVR measurements at various vascular baselines ([@B33]), and may in a small part underlie the BOLD response behavior in the "vascular steal" phenomenon ([@B72]). This limitation will require careful consideration in the presence of known vascular dysfunction ([@B3]).

A critical assumption for CVR mapping is that PETCO~2~ represents PaCO~2~. However, PaCO~2~ is determined by both inhaled CO~2~ and the minute ventilation. Low cardiac output can increase alveolar dead space, which would increase the difference between PaCO~2~ and PETCO~2~ ([@B70]), leading to underestimations of PETCO~2~-based CVR. In addition, PETCO~2~ is shown to overestimate PaCO~2~ during exercise in young adults, but not in older adults ([@B82]). Moreover, PETCO~2~-related CVR is known to follow a circadian rhythm, increasing with the level of alertness ([@B1]). These factor contribute to inter-cohort, inter-sessional and inter-subject variability in CVR estimates that must be accounted for when assessing true differences in CVR.

In this regard, an emerging research direction is building normative CVR atlases that allow the significance of CVR deviations to be assessed ([@B73]). Such atlases would ideally encompass not only quantitative CVR values but also CVR-timing information ([@B79]). This is a critical step in expanding the clinical utility of CVR maps, and atlases will likely need to be specific to the CO~2~ delivery method, stimulation design, study objectives and MRI system used.

The above research gaps pertain not only to AD but to other cerebrovascular diseases also. The increasing awareness of the vascular etiology of various forms of dementia will highlight these limitations and prompt more focused validation studies.
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